Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women

Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women

Esteban Jódar-GimenoEndocrinology and Metabolism Service, University Hospital “12 de Octubre”, Madrid, Spain. Associate Professor of Medicine Universidad Complutense, Madrid, SpainObjective: To review the pharmacological properties and the available clinical data of fu...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Esteban Jódar-Gimeno
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2007
Materias:
Geriatrics
RC952-954.6
Acceso en línea:https://doaj.org/article/db7b65187e6848e9aa0d3b5e1678ef81
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:db7b65187e6848e9aa0d3b5e1678ef81
record_format dspace
spelling oai:doaj.org-article:db7b65187e6848e9aa0d3b5e1678ef812021-12-02T07:15:30ZFull length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women1178-1998https://doaj.org/article/db7b65187e6848e9aa0d3b5e1678ef812007-04-01T00:00:00Zhttps://www.dovepress.com/full-length-parathyroid-hormone-1ndash84-in-the-treatment-of-osteoporo-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Esteban Jódar-GimenoEndocrinology and Metabolism Service, University Hospital “12 de Octubre”, Madrid, Spain. Associate Professor of Medicine Universidad Complutense, Madrid, SpainObjective: To review the pharmacological properties and the available clinical data of full length parathyroid hormone (PTH) in post-menopausal osteoporosis.Sources: A MEDLINE search was completed, together with a review of information obtained from the manufacturer and from the medicine regulatory agencies.Study and data selection: Studies were selected according to relevance and availability. Relevant information (design, objectives, patients’ characteristics, outcomes, adverse events, dosing, etc) was analyzed.Results: Different studies have shown that, when administered intermittently as a subcutaneous injection in the abdomen, PTH increases bone mineral density (BMD) and prevents vertebral fractures. On completion of PTH therapy (up to 24 months), there is evidence that sequential treatment with alendronate is associated with a therapeutic benefit in terms of increase in BMD. Further trials are necessary to determine long-term safety and the role of PTH in combination with other treatments for osteoporosis and the effect of repeated cycles of PTH followed by an anti-catabolic agent. There are currently no completed comparative trials with other osteoporosis treatments.Conclusions: Full length PTH, given intermittently as an abdominal subcutaneous injection, appears to be a safe and efficacious treatment option for high risk osteoporosis. More data are needed to determine its specific role in osteoporosis treatment.Keywords: postmenopausal osteoporosis, anabolic therapy, PTH (1–84)Esteban Jódar-GimenoDove Medical PressarticleGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 2, Pp 163-174 (2007)
institution DOAJ
collection DOAJ
language EN
topic Geriatrics
RC952-954.6
spellingShingle Geriatrics
RC952-954.6
Esteban Jódar-Gimeno
Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women
description Esteban Jódar-GimenoEndocrinology and Metabolism Service, University Hospital “12 de Octubre”, Madrid, Spain. Associate Professor of Medicine Universidad Complutense, Madrid, SpainObjective: To review the pharmacological properties and the available clinical data of full length parathyroid hormone (PTH) in post-menopausal osteoporosis.Sources: A MEDLINE search was completed, together with a review of information obtained from the manufacturer and from the medicine regulatory agencies.Study and data selection: Studies were selected according to relevance and availability. Relevant information (design, objectives, patients’ characteristics, outcomes, adverse events, dosing, etc) was analyzed.Results: Different studies have shown that, when administered intermittently as a subcutaneous injection in the abdomen, PTH increases bone mineral density (BMD) and prevents vertebral fractures. On completion of PTH therapy (up to 24 months), there is evidence that sequential treatment with alendronate is associated with a therapeutic benefit in terms of increase in BMD. Further trials are necessary to determine long-term safety and the role of PTH in combination with other treatments for osteoporosis and the effect of repeated cycles of PTH followed by an anti-catabolic agent. There are currently no completed comparative trials with other osteoporosis treatments.Conclusions: Full length PTH, given intermittently as an abdominal subcutaneous injection, appears to be a safe and efficacious treatment option for high risk osteoporosis. More data are needed to determine its specific role in osteoporosis treatment.Keywords: postmenopausal osteoporosis, anabolic therapy, PTH (1–84)
format article
author Esteban Jódar-Gimeno
author_facet Esteban Jódar-Gimeno
author_sort Esteban Jódar-Gimeno
title Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women
title_short Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women
title_full Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women
title_fullStr Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women
title_full_unstemmed Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women
title_sort full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women
publisher Dove Medical Press
publishDate 2007
url https://doaj.org/article/db7b65187e6848e9aa0d3b5e1678ef81
work_keys_str_mv AT estebanjoacutedargimeno fulllengthparathyroidhormone1ndash84inthetreatmentofosteoporosisinpostmenopausalwomen
_version_ 1718399547793735680

Ejemplares similares